INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Overcome Patient-Level Access Barriers For New Medicine

  Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.

• Industry Innovators: APAC's Sharp Advanced Therapeutics Edge

  APAC is rapidly advancing its role in the global therapeutics landscape, fueled by faster development models. Learn how this momentum is reshaping expectations for innovation and commercialization.

• Accelerating Technology Diffusion In Cell And Gene Therapy

  Unlike most other drugs, advanced therapies require complex, purpose-built supply chain networks. Making them requires cross-sector collaboration.

• Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real

  Mesoblast's Silviu Itescu shares how two decades of rigorous science and manufacturing turned allogeneic MSCs into the first FDA-approved cell therapy while building a scalable platform for inflammatory diseases such as GvHD, back pain, and heart failure.

• The Value Of Real-World Evidence In Canadian Drug Commercialization

  Leveraging real-world evidence (RWE) across the product lifecycle enables manufacturers to fill the evidence gap beyond RCTs to help guide local commercial strategic planning and market access strategy.

• A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?

  In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.

• Advancing Off-The-Shelf CRISPR CAR-T Therapies Into The Community Setting With Caribou Biosciences' Rachel Haurwitz

  On episode 120 of Cell & Gene: The Podcast, Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies.

• ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026

  ARM's Tim Hunt outlines how smarter regulation, evolving payment models, and global competition are reshaping CGT into a more accessible and commercially sustainable industry.

• Increase Agility By Integrating Drug Substance And Drug Product

  Biopharma success depends on agility. Move efficiently from discovery to delivery by co-locating drug substance and drug product operations, reducing transfer risks and accelerating your timeline

• Why Flexible, Collaborative Distribution Partners Matter For CGTs

  Learn how collaborative distribution models manage reimbursement hurdles and complex delivery requirements to ensure patient access and long-term commercial success.